LRMR Share Price | Larimar Therapeutics, Inc. Stock Analysis & Recommendation

Q: How big is Larimar Therapeutics, Inc.?

Market Cap: As of Jun 18, Larimar Therapeutics, Inc. has a market capitalization of 172.24 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Larimar Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -95.23 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 171.81 million and total assets of 200.93 million.

Q: What does Larimar Therapeutics, Inc. do?

Overview: Larimar Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for complex rare diseases using its cell penetrating peptide technology platform, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap.Financial Snapshot: Most recent Net Profit: -29 Million (Quarterly Results - Mar 2025) Market cap: USD 172.24 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.08 Return on Equity: -66.01% Price to Book: 1.19Contact Details: Address: THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD PA: 19004 Tel: 1 617 6224003 Fax: 1 302 6555049 Website: https://larimartx.com/

Q: Is Larimar Therapeutics, Inc. technically bullish or bearish?

As of 29 August 2025, the technical trend for Larimar Therapeutics, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD and Bollinger Bands indicate a bullish stance, while the monthly MACD and KST are bearish, suggesting mixed signals across different time frames. The daily moving averages are bullish, supporting the overall mildly bullish outlook. The stock has outperformed the S&P 500 over the past week and month, returning 2.64% and 9.74% respectively, but has underperformed over the longer term, with a 1-year return of -37.52% compared to the S&P 500's 17.14%.

Results Declared: Larimar Therapeutics, Inc. has declared results on 19 Mar 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.93 M

Shareholding (Dec 2025)

FII

3.92%

Held by 54 FIIs

DII

38.88%

Held by 23 DIIs

Promoter

43.92%

How big is Larimar Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Larimar Therapeutics, Inc. has a market capitalization of 172.24 million, with net sales of 0.00 million and a net profit of -95.23 million over the latest four quarters. The company reported shareholder's funds of 171.81 million and total assets of 200.93 million as of Dec 24.

View full answer

What does Larimar Therapeutics, Inc. do?

22-Jun-2025

Larimar Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases using cell penetrating peptide technology. It has a market cap of $172.24 million and reported a net profit loss of $29 million as of March 2025.

View full answer

Who are in the management team of Larimar Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Larimar Therapeutics, Inc. includes Mr. Joseph Truitt (Chairman), Dr. Carole Ben-Maimon (President and CEO), and Board members Mr. Thomas Hamilton, Mr. Jonathan Leff, Dr. Thomas Daniel, and Mr. Frank Thomas.

View full answer

Is Larimar Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 29, 2025, Larimar Therapeutics, Inc. shows a mildly bullish trend with daily moving averages and weekly indicators supporting this outlook, despite mixed signals from monthly metrics and a one-year return of -37.52% compared to the S&P 500's 17.14%.

View full answer

Compare Larimar Therapeutics, Inc. with Similar Stocks

Ikena Oncology, Inc.Carisma Therapeutics, Inc.Neoleukin Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 465 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.25

Return on Equity

-94.94%

Price to Book

3.34

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-62 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

19.69%

6 Months

5.41%

1 Year

84.25%

2 Years

-42.15%

3 Years

6.12%

4 Years

15.84%

5 Years

-72.65%

Larimar Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-220.43%

EBIT to Interest (avg)

-51.78

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.08

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

90.52%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.34

EV to EBIT

-2.08

EV to EBITDA

-2.08

EV to Capital Employed

-8.24

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-94.94%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

Bearish

No Signal

Bollinger Bands

Bullish

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bullish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 29 Schemes (13.29%)

Foreign Institutions

Held by 54 Foreign Institutions (3.92%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -117.01% vs -121.54% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-63.90",
          "val2": "-31.20",
          "chgp": "-104.81%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-62.50",
          "val2": "-28.80",
          "chgp": "-117.01%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -105.58% vs -118.43% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-172.10",
          "val2": "-90.60",
          "chgp": "-89.96%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-165.70",
          "val2": "-80.60",
          "chgp": "-105.58%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-63.90

-31.20

-104.81%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-62.50

-28.80

-117.01%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -117.01% vs -121.54% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-172.10

-90.60

-89.96%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-165.70

-80.60

-105.58%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -105.58% vs -118.43% in Dec 2024

All Annual Results

Company CV

About Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Larimar Therapeutics Inc., formerly Zafgen, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for complex rare diseases using its cell penetrating peptide technology platform. The Company’s protein replacement therapy platform provides disease-modifying therapies that intends to deliver missing proteins inside the machinery of cells to treat devastating rare diseases that have no treatments available. The Company’s lead product candidate, CTI-1601, is a recombinant fusion protein intended to deliver human frataxin (FXN) into the mitochondria of patients with Friedreich’s ataxia (FA). CTI-1601 is in Phase I clinical program. The Company intends to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.

Company Coordinates

Company Details

THREE BALA PLAZA EAST. SUITE 506 , BALA CYNWYD PA : 19004

Tel: 1 617 6224003

https://larimartx.com/

Registrar Details